Experimental combo aims to help leukemia patients reach transplant
NCT ID NCT07297173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether giving chemotherapy followed by an infusion of immune cells from a partially matched donor can help patients with relapsed or refractory leukemia get to a stem cell transplant. Only 5 participants will be enrolled to check safety and side effects like graft-versus-host disease and infections. The goal is to find a better way to control the disease long enough for a transplant to work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLA-mismatched G-CSF mobilized peripheral blood mononuclear cells (donor immune cells)
What this could lead to
If successful, this approach could help more patients with hard-to-treat leukemia get to a stem cell transplant and possibly achieve long-term disease control.
What could go wrong
This is a very early Phase 1 trial with only 5 people, so safety and effectiveness are not yet known. There are serious risks like graft-versus-host disease and severe infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact